Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
BUSINESS
Torii Upwardly Revises Profit Forecast for 1st Half of FY2012
Torii Pharmaceutical announced on October 17 upward revisions for its business forecasts for the first half of FY2012 (April to September 2011). Profits are expected to exceed the previous forecast since selling, general, and administrative (SGA) expenses such as R&D…
To read the full story
BUSINESS
- Genmab Targets 2027 US Debut for 2 Cancer Drugs, CEO Eyes Blockbuster Potential
April 23, 2026
- Bayer Eyes 2026 Launch for Sevabertinib under “3-Plus-3” Strategy in Japan
April 23, 2026
- iPark, Taiwan’s ITRI Ink MOU to Boost Biotech Collaboration
April 23, 2026
- AbbVie, BioLabs Partner to Support Japan Biotech Startups
April 23, 2026
- Lenvima-Keytruda Triplets Fail in First-Line RCC Trial
April 22, 2026
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s FY2026 drug pricing reform is set to usher in a new phase for the generics market, effectively bringing an…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…